Bristol-Myers opens up the Phase 0 pathway in testing its new cancer therapies, following in Celgene’s footsteps
Finding out as much as you can as fast as you can about your new cancer drug has become a major theme in oncology R&D, where billions can lie on the line — depending on the ultimate success of your rapid-fire development strategy. And few major league pharma outfits understand that challenge better than Bristol-Myers Squibb, which has faced more than its share of misdirections on strategy.
So it’s particularly interesting to see Bristol-Myers tie-up with Seattle-based Presage Biosciences on Phase O testing, which will use microdoses of multiple drugs and combos on patients to gauge their pharmacodynamic effects. That way researchers can help determine if they’re on the right track as they lay out plans to develop drugs in much more extensive studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
